These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 23933602)

  • 21. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
    Kunze B; Wein F; Fang HY; Anand A; Baumeister T; Strangmann J; Gerland S; Ingermann J; Münch NS; Wiethaler M; Sahm V; Hidalgo-Sastre A; Lange S; Lightdale CJ; Bokhari A; Falk GW; Friedman RA; Ginsberg GG; Iyer PG; Jin Z; Nakagawa H; Shawber CJ; Nguyen T; Raab WJ; Dalerba P; Rustgi AK; Sepulveda AR; Wang KK; Schmid RM; Wang TC; Abrams JA; Quante M
    Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bile acids are multifunctional modulators of the Barrett's carcinogenesis.
    Burnat G; Majka J; Konturek PC
    J Physiol Pharmacol; 2010 Apr; 61(2):185-92. PubMed ID: 20436219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
    Yen CJ; Izzo JG; Lee DF; Guha S; Wei Y; Wu TT; Chen CT; Kuo HP; Hsu JM; Sun HL; Chou CK; Buttar NS; Wang KK; Huang P; Ajani J; Hung MC
    Cancer Res; 2008 Apr; 68(8):2632-40. PubMed ID: 18413730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma--a possible biomarker to predict the malignant potential of Barrett's oesophagus.
    Iwaya Y; Hasebe O; Koide N; Kitahara K; Suga T; Shinji A; Muraki T; Yokosawa S; Yamada S; Arakura N; Tanaka E; Nakayama J
    Histopathology; 2014 Mar; 64(4):536-46. PubMed ID: 24117499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma.
    Morita S; Matsumoto Y; Okuyama S; Ono K; Kitamura Y; Tomori A; Oyama T; Amano Y; Kinoshita Y; Chiba T; Marusawa H
    Carcinogenesis; 2011 Nov; 32(11):1706-12. PubMed ID: 21890457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim.
    Kan T; Sato F; Ito T; Matsumura N; David S; Cheng Y; Agarwal R; Paun BC; Jin Z; Olaru AV; Selaru FM; Hamilton JP; Yang J; Abraham JM; Mori Y; Meltzer SJ
    Gastroenterology; 2009 May; 136(5):1689-700. PubMed ID: 19422085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenesis of Barrett esophagus: deoxycholic acid up-regulates goblet-specific gene MUC2 in concert with CDX2 in human esophageal cells.
    Hu Y; Jones C; Gellersen O; Williams VA; Watson TJ; Peters JH
    Arch Surg; 2007 Jun; 142(6):540-4; discussion 544-5. PubMed ID: 17576890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exposure of Barrett's and esophageal adenocarcinoma cells to bile acids activates EGFR-STAT3 signaling axis via induction of APE1.
    Bhat AA; Lu H; Soutto M; Capobianco A; Rai P; Zaika A; El-Rifai W
    Oncogene; 2018 Nov; 37(46):6011-6024. PubMed ID: 29991802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.
    Dvorak K; Watts GS; Ramsey L; Holubec H; Payne CM; Bernstein C; Jenkins GJ; Sampliner RE; Prasad A; Garewal HS; Bernstein H
    Am J Gastroenterol; 2009 Feb; 104(2):302-9. PubMed ID: 19174784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts.
    Guan B; Li H; Yang Z; Hoque A; Xu X
    Cancer; 2013 Apr; 119(7):1321-9. PubMed ID: 23280144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
    Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
    J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells.
    Liu T; Zhang X; So CK; Wang S; Wang P; Yan L; Myers R; Chen Z; Patterson AP; Yang CS; Chen X
    Carcinogenesis; 2007 Feb; 28(2):488-96. PubMed ID: 16990345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. APE1-mediated DNA damage repair provides survival advantage for esophageal adenocarcinoma cells in response to acidic bile salts.
    Hong J; Chen Z; Peng D; Zaika A; Revetta F; Washington MK; Belkhiri A; El-Rifai W
    Oncotarget; 2016 Mar; 7(13):16688-702. PubMed ID: 26934647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
    von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
    Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
    Weimann A; Zimmermann M; Gross M; Slevogt H; Rieger A; Morawietz L
    Int J Surg Pathol; 2010 Oct; 18(5):330-7. PubMed ID: 20444732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage.
    Zhou Z; Lu H; Zhu S; Gomaa A; Chen Z; Yan J; Washington K; El-Rifai W; Dang C; Peng D
    J Exp Clin Cancer Res; 2019 Jan; 38(1):13. PubMed ID: 30626422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma.
    Song S; Guha S; Liu K; Buttar NS; Bresalier RS
    Gut; 2007 Nov; 56(11):1512-21. PubMed ID: 17604323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression changes associated with Barrett's esophagus and Barrett's-associated adenocarcinoma cell lines after acid or bile salt exposure.
    Hao Y; Sood S; Triadafilopoulos G; Kim JH; Wang Z; Sahbaie P; Omary MB; Lowe AW
    BMC Gastroenterol; 2007 Jun; 7():24. PubMed ID: 17597535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.